Given that NFκB activation is closely linked to the upregulation of inflammatory cytokines and muscle degradation pathways, our findings suggest that ETAS® may exert protective effects against sarcopenia by modulating NFκB signaling and reducing inflammation-associated muscle loss. Here, NFKB1 is linked to sarcopenia.